Download Testing Services Markets, SNP Analysis, DNA Sequencing, Retail Clinics, Companion Diagnostics Brochure

Brochure
More information from http://www.researchandmarkets.com/reports/2860766/
Testing Services Markets, SNP Analysis, DNA Sequencing, Retail Clinics,
Companion Diagnostics
Description:
A perfect supplemental information resource for customers who have already purchased The Worldwide
Market for In Vitro Diagnostic Tests, 6th Edition, The IVD Market Research Supplement bundle studies and
quantifies in greater detail some of the important areas that will have a transforming impact on the
diagnostic industry:
Companies are now performing diagnostic tests as a service rather than simply selling kit to laboratories.
Are companies seeking profit, or a 'back-door' around FDA regulations? And does it have growth potential
as a strategy.
DNA sequencing and SNPs are essential for genetic testing, clearly the future of diagnostics. What
companies/products are dominating these areas, and what growth can be expected?
Retail clinics present an interesting venue for diagnostics to be sold; but there is confusion in the
marketplace about how many stores will open and what their impact will be.
Companion diagnostics, or theranostics has generated a lot of publicity- but what are the obstacles that
need to be overcome for the concept to work in the marketplace?
These questions have been tackled by Kalorama analysts in five reports. While the topics are touched on in
the 6th Edition, this bundle of reports, representing over 1,000 pages of market research, takes a more
detailed look.
Test Services Commercialization
SNP Analysis
Retail Clinics (contains POC and Immunoassay retail clinic sales information)
Companion Diagnostics
DNA Sequencing Equipment and Services
A bundle of five Kalorama Information reports, this resource, representing over 1,000 pages of information
on cutting-edge topics critical to the future of diagnostics, is available at a significant discount over the cost
of the five reports individually. The cost of these reports, purchased seperately with a single user license
would be over $16,000.
This resource is available to all buyers but the Kalorama editors believe this will be especially useful to
previous buyers of the The Worldwide Market for In Vitro Diagnostic Tests, 6th Edition, (which is not included
in this product, and would be purchased separately.)
The reports are grouped together into one electronic version, with a seperate table of contents for each
market report.
As with all Kalorama Information products, these five reports were created by professional analysts with
industry experience and were the result of both secondary (research into annual reports, medical literature,
trade press) and most importantly primary research (interviews with experts and executives) to obtain real
market insights. In several of these areas, SNPs, Retail Clinics and Test Services for instance, Kalorama has
been the first to publish meaningful research on the topics.
Contents:
DIAGNOSTIC TEST SERVICE COMMERCIALIZATION: A ROADMAP TO DIAGNOSTICS IN THE 21ST CENTURY
CHAPTER ONE: EXECUTIVE SUMMARY
Scope and Methodology
Market Trends
Clinical Chemistry
Coagulation tests
Flow Cytometry
Histology/Cytology
Infectious Diseases
Keys to Success
CHAPTER TWO: INTRODUCTION
Background
The U.S. Versus Europe
ASRs
Hospital Outreach and National Reference Lab Services
Lab Outreach Testing
Independent Laboratories
Status quo and Future
Tests in Development
Serendepity or Strategy?
CHAPTER THREE: MARKET OVERVIEW/ SUPPLY ANALYSIS
Background
Market Analysis, revenue estimates 2007 - 2012
Testing Markets
ISC and ISH
Market and Growth
Market Share
Lab Launches and Acquisitions
Market Leaders
Evaluation of Lab Tests
Uniqueness
Need
Reimbursed
Incumbent
Recognized
Peer Reviewed
Competition from FDA Cleared Products
Cost
Competitive Technologies
Pathwork
BRCA analysis
Mammastatin
Limited Use of Molecular Testing for Colon Cancer.
TDT
Ovarian Cancer Testing
Future Leaders?
HIV Testing
Mental Illness
Test Services on the Horizon
CHAPTER FOUR: MARKET TRENDS/ DEMAND ANALYSIS
The Commercialization of Multiplexed and Complex Analyses
Opportunity Pricing and margins are attractive Demand for Esoteric Tests
CHAPTER FIVE: MARKET BARRIERS FOR TEST SERVICES
Regulatory affairs
Can the FDA Regulate New test Modalities?
IVDMIAs
Pending LDT Legislation
Reimbursement Imperative
Physician Uptake
Connectivity, a Force to Consider
The In Vivo - In Vitro Diagnostic Paradigm
Social media and Internet-Based Services
CHAPTER SIX: TESTS AND COMPANIES TO WATCH
23andMe, Inc.
Key Comment
Details
Affymetrix
Key Comment
Details
Agendia B.V.
Key Comment
Details
ARUP Laboratories
Key Comment
Athena Diagnostics, Inc.
Key Comment
Details
Atherotech
Key Comment
Details
AviaraDx (formerly Arcturus Biosciences
Key Comment
Details
Biomedical Diagnostics, LLC/Abviva, Inc.
Key Comment
Details
Biophysical Corporation
Key Comment
Details
Caris MPI
Key Comment
Clarient Inc. (formerly ChromaVision
Key Comment
Detail
Clinical Data, Inc
Key Comment
Details
CombiMatrix Molecular Diagnostics (CMDX
Key Comment
Details
Consumer Genetic
Key Comment
Details
Corgenix Medical Corporatio
Key Comment
Details
Correlogic Systems, Inc
deCode Genetics Inc.
Details
DiagnoCure
Key Comment
Details
DNA Direct, Inc.
Key Comment
Details
EXACT Sciences Corporation
Key Comment
Details
Exiqon A/S
Key Comment
Details
Focus Diagnostics, Inc.
Key Comment
Details
Genelex Corporation
Key Comment
Details
Genomic Health
Key Comment
Details
Genoptix, Inc.
Key Comment
Details
Genzyme Corporation
Details
InterGenetics, Inc.
Key Comment
Details
Knome, Inc.
Key Comment
Details
Lab21 Healthcare
Key Comment
Laboratory Corporation of America Holdings (LabCorp)
Key Comment
Details
LipoScience, Inc.
Key Comment
Details
Mayo Medical Laboratories
Key Comment
Details
Monogram Biosciences, Inc. (formerly ViroLogic)
Key Comment
Details
Myriad Genetics, Inc.
Key Comment
Details
NeuroMark
Key Comment
Details
Nuvera Biosciences
Key Comment
Details
Nymox Pharmaceuticals
Details
Oncolab, Inc.
Key Comment
Details
Panacea Pharmaceuticals, Inc.
Key Comment
Details
Pathway Diagnostics Corporation
Key Comment
Details
Pathwork Diagnostics (formerly Predicant Biosciences)
Key Comment
Details
Perceptronix Medical Inc.
Key Comment
Details
Power3 Medical Products, Inc.
Key Comment
Details
Precision Therapeutics, Inc.
Key Comment
Details
Prometheus Laboratories Inc.
Key Comment
Details
Psynomics Incorporated
Key Comment
Details
Quest Diagnostics Incorporated
Key Comment
Details
Rational Therapeutics
Key Comment
Details
Rosetta Genomics Ltd.
Key Comment
Details
Signature Genomic Laboratories, LLC
Key Comment
Details
Smart Genetics
Key Comment
Details
Specialty Laboratories
Key Comment
Details
SpectraCell Laboratories, Inc.
Key Comment
Details
Targeted Diagnostics & Therapeutics, Inc. (TDT)
Key Comment
Details
XDx Inc.
Key Comment
Details
CHAPTER SEVEN: CONCLUSION
Is There a Market for Test Services?
Strategies for Successful Market Entry
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Figure 1-1: Sales of 7 Key IVD Segments (Clinical Chemistry, Immunoassays, Radioimmunassays, Coagulation,
Histology/Cytology, Nucelic Acid Assays, Flow Cytometry) vs. Their Esoteric Components, 2007
Figure 1-2: Growth Rate 7 IVD Segments (Clinical Chemistry, Immunoassays, Radioimmunassays,
Coagulation, Histology/Cytology, Nucelic Acid Assays, Flow Cytometry) vs. Their Esoteric Components , 2007
Figure 1-3: Esoteric Test Service Revenues, Reference Labs and CLIA-registered Company Test Service
Offerings, 2007 and 2012
CHAPTER TWO INTRODUCTION
Figure 2-1: Explosion of Test Capabilities 20th and 21st Century
CHAPTER THREE: MARKET OVERVIEW AND SUPPLY ANALYSIS
Table 3-1: Worldwide Esoteric Test Reagent Sales by Product Market, 2007
Figure 3-1: Esoteric Sales Across IVD Segments (Clinical Chemistry, Immunoassays, Radioimmunassays,
Coagulation, Histology/Cytology, Nucelic Acid Assays, Flow Cytometry), 2007
Table 3-2: Worldwide Test Servcies Market
Table 3-3: Esoteric and Genomic Service Test Sales, Selected Companies (Company, Location, Area, 20052008 sales, % of Change)
Table 3-4: Selected CLIA- Registered Company Lab Tests Evaluated Selected CLIA- mRegistered Company Lab
Tests Evaluated (Uniqueness, Need, Reimbursement, Incumbent Presence, Recognizable Technology, Peer
Reviewed)
Table 3-5: Selected CLIA-Registered Lab Test Services, 2007
CHAPTER FOUR: MARKET TRENDS AND DEMAND ANALYSIS
Table 4-1: Number of People Who Get Chronic Diseases Every Year
SNP GENOTYPING AND ANALYSIS MARKETS
CHAPTER ONE: EXECUTIVE SUMMARY
What is a SNP?
Applications
The Market
Competitive Analysis
Challenges
Scope and Methodology
CHAPTER TWO: INTRODUCTION
Background
SNP Analysis Methods
Amplification
Allele discrimination / assay reaction mechanism
Single Nucleotide Addition; Pyrosequencing
Assay Format
Detection Method
Scope and Methodology
Definitions
DNA Microarray
Genome-Wide Association
Linkage Analysis
Mass Spectrometry
Single-Nucleotide Polymorphism (SNP)
CHAPTER THREE: APPLICATIONS
Life Science Research
Pharmacogenetics / Pharmacogenomics
Case Study #1 -- SNPs in Gene for P-glycoprotein Affect Antidepressant Response
Case Study #2 - Celera Studying SNPs Associated With Heart Disease
Case Study #3 - Synonymous SNPs Alter mRNA Splicing with Obesity
Case Study #4 - University of Ottawa Heart Institute (UOHI) Coronary Artery Disease Research
CHAPTER FOUR: INDUSTRY AND REGULATORY TRENDS
Industry Trends
Consolidation Occurring in Array and Life Science Markets
FDA Involvement Making Drug Industry More Comfortable
Acceptance of SNP Analysis, Pharmacogenetics Reached Tipping Point
Core Labs Becoming Established Paradigm
Technology Trends
Increased Multiplexing Expands Applications
End-Users Attracted to Larger-Scale SNP Platforms
Complexity of Biological Systems Requires Multiple Techniques
Miniaturization of Equipment and Instruments
Regulatory Trends
Introduction
Critical Path Initiative
March 2005 - “Guidance for Industry - Pharmacogenomic Data Submissions”
April 2005 - “Drug-Diagnostic Co-Development Concept Paper”
March 2006 - Critical Path Opportunities List
November 2006 - “Recommendations for the Generation and Submission of Genomic Data”
August 2007 - “Pharmacogenomic Data Submissions — Companion Guidance”
August 2007 - FDA Updates Labeling of Warfarin (Coumadin)
December 2007 - EGAPP Reviews Use of CYP450 Genetic Testing For SSRIs
CHAPTER FIVE: PRODUCTS
Affymetrix
Overview of Affymetrix Products
Hardware
Applied Biosystems
Overview of Applied Biosystems Products
Assays and Reagent
Instruments
Beckman Coulter
CombiMatrix
febit
GE Healthcare
Illumina
Hardware
Microarrays
LI-COR Biosciences (Lincoln, NE)
Roche Applied Science
Sequenom
Services
Agencourt Biosciences
DNAPrint Genomics
Polymorphic DNA Technologies
Software
Applied Biosystems
Premier Biosoft
Public Tools
CHAPTER SIX: CONSORTIA, GOVERNMENT INVOLVEMENT, DEALS
Consortia, Collaborative Projects
The Cancer Genome Atlas (TCGA) Pilot Project
Cancer Sequencing Project
Critical Path Institute
DNA Polymorphism Discovery Resource
Genetic Association Information Network (GAIN)
Genotype-To-Phenotype Database (GEN2PHEN)
International HapMap Project
Introduction & Background
Rationale for HapMap Approach
Process for Producing HapMap
Populations Included in HapMap
Measures Taken to Protect Donors’ Privacy
Laboratories and Technologies Involved in HapMap
Practical Use of the HapMap Data
MicroArray Quality Control (MAQC) Project
NIH Roadmap
NIH Roadmap for Medical Research
Pharmacogenetics Research Network (PGRN)
NIH Involvement, Funding for SNPs and Sequencing
Funding for Sequencing Projects Affecting SNP Market
Continued Rapid Growth in Sequence Production
Funding and Consortia for Sequencing
NHGRI Funds Large-Scale Sequencing Centers, 2006
Competitive Activity
CHAPTER SEVEN: MARKET DATA AND COMPETITIVE ANALYSIS
Historical
Illumina as Bellwether for SNP Analysis Market
Applied Biosystems as Bellwether for RT-PCR Products
Forecast
Assumptions
SNP Revenues by Region
SNP Revenues by Product
Competitive Analysis
CHAPTER EIGHT: CORPORATE PROFILES
Affymetrix
Applied Biosystems
Illumina
CHAPTER NINE: CHALLENGES AND STRATEGIC RECOMMENDATIONS
Challenges
Cheaper Sequencing Creates Competition for SNP Analysis Platforms
Market Is Dominated by a Small Number of Suppliers
Issues Arise With Use of Public Databases
Data Management Requirements Limit Large-Scale Technologies
Diagnostic Market Holds Obstacles For New Innovations
Backlash Against Rush Into Genetic Testing, DTC Marketing
Standard Processes for SNP Experiments Still Not Established
Shortcomings in Sample Preparation and Handling Hinder Success
Privacy Concerns Pose Threat to Broad Technology Adoption
Strategic Recommendations
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Figure-1-1: SNP Analysis Market 2007-2013
Figure 1-2: Growth Rate in SNP Analysis Revenues 2008-2013
CHAPTER TWO: INTRODUCTION
Table 2-1 Adelle-Specific Invasive Cleavage
Table 2-2 Adelle-Specific Ligation
Table 2-1 Allele-Specific Primer Extension
Table 2-4 Single Base Primer Extension
CHAPTER FOUR: INDUSTRY AND REGULATORY TRENDS
Table 4-1: Critical Path Opportunities List
CHAPTER FIVE: PRODUCTS
Figure 5-1: Taq Man Assay
Figure 5-2: SOLID System Average Throughput Progress
Figure 5-3: SNPstream Method
Figure 5-4: Roche SimpleProbe System
Figure 5-5: Roche HybProbe System
Table 5-1 Products in the SNP Analysis Market
Table 5-2 Public SNP Tools and Resources (Tool, Website)
CHAPTER SIX: CONSORTIA, GOVERNMENT INVOLVEMENT, DEALS
Figure 6-1: Domains of Genomes Sequenced by Year (Archaea, Bacteria, Eukaryota) Major Sequencing
Centers, Jan 2008
Figure 6-5: Top Funding Agencies, DNA Sequencing, 2008
Figure 6-4: Major Sequencing Centers and Percent of Sequencing Projects (WORLD, GENOSCOPE, BMC,
Sanger, WashU, BROAD, JCVI, JGI), Jan 2008
Figure 6-5: Top Funding Agencies, DNA Sequencing, 2008 ($M)
Figure 6-6: Human Genome Project Funding, DOE& NIH ’90-‘03
Figure 6-7: Areas Funding Genome Sequencing, Jan 2008 (Medical, Evolutionary, Agricultural, Environmental,
Biotechnology)
Table 6-5: Large-Scale Sequencing Centers, NHGRI Funding, 2004-2006
Figure 6-8: Top Genome Sequencing Countries, Jan. 2008 (# projects)
Figure 6-9: SNP Analysis Related Deals (Companies, Date, Details of Deal)
Figure 6-10: SNP: NHGRI Funded Large-Scale Sequencing Ctrs, ‘07
Table 6-6: SNP Analysis-Related Deals (Companies, Date, Details of Deal)
CHAPTER SEVEN: MARKET DATA AND COMPETITIVE ANALYSIS
Figure 7-1: Illumina Quarterly Revenues, 2001-2007 ($M)
Figure 7-2: Applied Biosystems Revenues in Real Time PCR/Applied Genomics
Table-7-1: Forecasted Revenues in the SNP Analysis Market
Figure-7-3: Forecasted Revenues in the SNP Analysis Market
Table 7-2: Growth Rate in SNP Analysis Tools Market, 2008-2013
Figure 7-4: Growth Rate in SNP Analysis Tools Market, 2008-2013
Figure 7-5: SNP Analysis Revenues by Region (North America, Europe, Rest of World)
Table 7-3: SNP Analysis Revenues by Region (North America, Europe, Rest of World)
Figure 7-6 SNP Market by Product Segment (Instruments, Consumables, Software & Services)
Table 7-4: SNP Market by Segment (Instruments, Consumables, Software & Services)
Table 7-5: Revenues Among the Top Companies in SNP Analysis (Illumina, Affymetrix, Applied Biosystems,
Other)
Figure 7-7: SNP Analysis Market Share, 2007
CHAPTER EIGHT: CORPORATE PROFILES
Figure 8-1: Affymetrix’ Revenues by Product Type, 2004 - 2007
Figure 8-2: Illumina BeadStation Installed Base, 2004-2006
CHAPTER NINE: CHALLENGES AND STRATEGIC RECOMMENDATIONS
Figure 9-1: Estimated Decrease in Screening Price
COMPANION DIAGNOSTICS MARKETS (A REALISTIC ASSESSMENT OF THE OPPORTUNITIES, CHALLENGES, KEY
PLAYERS AND IMPORTANT TRENDS IN PERSONALIZED MEDICINE)
CHAPTER ONE: EXECUTIVE SUMMARY
Background
Potential Benefits of Companion Diagnostics
Pitfalls of Personalized Medicine
Scope and Methodology
Market Factors and Estimates
Drivers For Companion Diagnostics
Assumptions
Important Trends
Possible Tactic: Royalty Model
CHAPTER TWO: OVERVIEW OF COMPANION DIAGNOSTICS
Personalized Medicine
Potential Benefits
Privacy and Public Perception
Biomarkers and Companion Diagnostics
Types of Biomarkers
CHAPTER THREE: APPLICATIONS OF COMPANION DIAGNOSTICS
Pharmacogenetics and Pharmacogenomics
Historical Basis
Current Techniques
Requirements
Cost-effectiveness
Applications
The Cytochrome System
Cancer
Amgen
UAMS Multiple Myeloma Project
DakoAssay for TOP2A
GE and Eli Lilly
Epigenomics and Abbott
Celera and Merk
bioMerieiux and Ipsen
Acute Lymphoblastic Leukemia
Regulatory Agencies
Applications of Genome More Challenging Than Expected
Cardiovascular Disease
RAS polymorphisms With Drug Effectiveness
Pgp
Thiazide diuretics
825T allele
HIT
Statins
Psychiatry and Pharmacogenetics/Pharmacogenomics
Is Herceptin a Paradigm?
A Balancing Act Between the Players
CHAPTER FOUR: MAJOR WORLD MARKET FACTORS AND DATA FOR COMPANION DIAGNOSTICS
Estimating Market Potential
Associated Testing
The Needs of Pharma and of Diagnostic Companies
Questions Determining Companion Diagnostics Growth
A Partial Change in Attitude
Intellectual Property
Cancer Market Potential Estimate
Ideal Market Potential - Cancer, Heart Disease, Psychiatric
Source: Kalorama Information
Challenges Unique to Companion Diagnostics
Privacy Concerns
Fear of Learning About Diseases
Use of Remnant Samples
Avoiding Pitfalls of Market Calculation
Companion Diagnostics Not Linked to Molecular Diagnostics
Demonic and SNP Analysis
Considering Time of Cooperative Development
Market Realities to Consider
Possible Tactic: Royalty Model
CHAPTER FIVE: COMPANY SUMMARIES
Overview
Abbott (Molecular) Diagnostics Subsidiary of Abbott Laboratories
Affymetrix, Inc.
Agilent Technologies, Inc
Althea Technologies, Inc.
Curidium Medica plc
Dako
Gen Probe
Genzyme Corporation
Ipsogen SAS
Lipomics Technologies, Inc.
Osmetech plc
Perlegen Sciences
Provista Life Sciences
Qiagen NV
Singulex, Inc.
Theranostics Health
Ventana Medical Systems
CHAPTER SIX: CONCLUSIONS AND STATEGIC IMPLICATIONS
First Conclusion
Implications:
Second Conclusion
Implications:
Third Conclusion
Implications:
Fourth Conclusion
Implications:
Fifth Conclusion
Implications:
Sixth Conclusion
Implications:
Seventh Conclusion
Implications:
Eighth Conclusion
Implications:
Ninth Conclusion
Implications:
Tenth Conclusion
Implications:
APPENDIX: GLOSSARY OF TERMS AND ABBREVIATIONS
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1: Market Projections for Companion Diagnostics* in the United States: 2008 - 2018
Figure 1-1: Market Projection Trends for Companion Diagnostics in the United States: 2008 - 2018
CHAPTER THREE: APPLICATIONS OF COMPANION DIAGNOSTICS
Table 3-1 Companion Diagnostics Groups
Table 3-3: Frequency of Recessive Traits
Table 3-4: Existing Cancer Drugs Complimentary to Companion Diagnostics
Table 3-5: Recent Activities in Companion Diagnostics
CHAPTER FOUR: MAJOR WORLD MARKET FACTORS AND
DATA FOR COMPANION DIAGNOSTICS
Table 4-1: The Ideal Potential Companion Diagnostics Markets for Cancer Therapeutics: 2008
Figure 4-1: The Ideal Potential Companion Diagnostics Markets for Cancer Therapeutics: 2008
Table 4-2: The Ideal Potential Companion Diagnostics Markets for Therapeutics Addressing the Top Four,
High-Profile Cancers: 2008
Figure 4-2: The Ideal Potential Companion Diagnostics Markets forTherapeutics Addressing the Top Four,
High-Profile Cancers: 2008
Figure 4-3: The Ideal Companion Diagnostics Market (Ideal vs. Likely to Benefit)
Figure 4-4 Subset of Ideal Market Likely to Benefit From Pharmaceutical Intervention (Likely to Benfit vs.
Realistic Market)
Table 4-3: Market Projections for Companion Diagnostics* in the United States: 2008 - 2018
Figure 4-1: Market Projection Trends for Companion Diagnostics* in the United States: 2008 - 2018
CHAPTER SIX: CONCLUSIONS AND STATEGIC IMPLICATIONS
Table 6-1: Hypothetical Cancer Therapy Outcome Based on Associated Genes
RETAIL CLINICS, THE EMERGING MARKET FOR CONVENIENCE AND IN-STORE HEALTHCARE
CHAPTER ONE: Executive Summary
Healthcare Reform
The Emergence of Retail Clinics
Establishing a Retail Clinic
Service Providers
Suppliers
Clinical Chemistry and Immunoassays
Vaccines
Indirect Revenues
Types of Retail Outlets Offering Clinics
Drug Stores
Supermarkets and Food Stores
Mass Merchandisers
Other Outlets
Issues And Trends
Competition with Primary Care Providers
Regulation
Development of Standards
Expansion of Services
Labor Shortages
Scope and Methodology
CHAPTER TWO: Introduction
The U.S. Healthcare System Today
Overview
Public Health Care
Private Health Care
The Need For Alternatives
High Cost of Care
Inconsistent Quality of Care
Delays to Treatment
Advertising and Promotion
Insurance
Consumer Response
Growth Drivers
Economic Pressures on Consumers
Consumer Responsibility for Health Care
Benefits of Prevention
Challenges
Standards of Care
Patient Flow
Medical Community Response
Reaction from Managed Care Organizations
Ability to Meet Financial Expectations
Establishing A Retail Clinic
Alliances
CHAPTER THREE: Service Providers
The Industry
Convenience Clinic Sales Forecasts
The Market
Competitive Positions of Key Players
CHAPTER FOUR: OPPORTUNITIES FOR DIAGNOSTIC AND PHARMACEUTICAL COMPNIES
Point of Care Tests
The Industry
Competitive Positions of Key Players
Convenience Clinic Sales Forecasts
Clinical Chemistry and Immunoassays
The Industry
Competitive Positions of Key Players
Convenience Clinic Sales Forecasts
Vaccines
The Industry
Competitive Positions of Key Players
Convenience Clinic Sales Forecasts
CHAPTER FIVE: Retail Outlets
Drug Stores
The Industry
Competitive Positions of Key Players
Convenience Clinic Sales Forecasts
Food Stores
The Industry
Competitive Positions of Key Players
Convenience Clinic Sales Forecasts
Mass Merchandisers
The Industry
Competitive Positions of Key Players
Convenience Clinic Sales Forecasts
Other Outlets
The Industry
Competitive Positions of Key Players
Convenience Clinic Sales Forecasts
CHAPTER SIX: Total Market
Growth of Retail Clinics
Opportunities for Suppliers
Increased Revenue for Retailers
CHAPTER SEVEN: Issues and Trends
Competition With Primary Care Providers
Regulation
Overview
Regulation of Convenience Clinics
Pending Legislation
Development of Standards
Expansion of Services
Labor Shortages
CHAPTER EIGHT: Company Profiles
Atlanticare
Aurora Quick Care
Checkups
Early Solutions Clinic
MedBasics
Minute Clinic
My Healthy Access
Quick Health
Now Medical Centers
Rediclinic
SmartCare Family Medical Centers
Solantic
Take Care Health Systems
Target Clinic Medical Associates
The Little Clinic
APPENDIX
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Figure 1-1: Estimated Number of U.S. Convenience Clinics, 2007 - 2011
Figure-1-2: Locations of Retail Clinics, 2007
Figure 1-3: Indirect Revenue to Drug Stores, Supermarkets, Mass Merchandising Outlets and Others with
Retail Clinics
CHAPTER TWO: INTRODUCTION
Figure 2-1: National Health Expenditures (NHE) and NHE as a Percent of GDP, 1980 - 2011
Figure 2-2: Premium Increases vs. Increases in Workers Earnings and Prices, 1989 - 2005
Figure 2-3: Unnecessary Deaths Resulting From Variations in Health Care Quality
Figure 2-4: HEDIS Scores by Quality of Health Care Plan, 2006
Figure 2-5: Change in Out of Pocket Health Care Expenses for Medicaid Recipients, 1997 - 2002
Figure 2-6: Out of Pocket Health Care Expenses for Disabled and Non-Disabled Medicaid Recipients, 1997 vs.
2002
Figure 2-7: Proportion of Adults Under Age 65 With Chronic Conditions, 2003
Table 2-2: U.S. Health Care Coverage by State, 2007
Table 2-3: Cost Savings From Medical Tourism, 2007
Table 2-4: Estimated Number of U.S. Convenience Clinics, Expansion of U.S. Convenience Clinics by Major
Chain (Aurora, QuickCare, Healthy Access, Minute Clinic, Quick Health, Solantis, Target Clinical, CheckUps,
MedBasics, Now Medical Centers, RediClinic Others, Take Care Clinics, the Little Clinic) 2007 to 2011
Figure 2-8: Expansion of U.S. Convenience Clinics by Major Chain (Aurora QuickCare, Healthy Access, Minute
Clinic, Quick Health, Solantis, Target Clinical, CheckUps, MedBasics, Now Medical Centers, RediClinic Others,
Take Care Clinics, the Little Clinic) 2007 to 2011
Table 2-5: Characteristics of Retail Outlets, 2007 (Drug Stores, Food Stores, Mass Merchandizing Outlets)
Table 2-6: Benefits and Drawbacks of Convenience Clinic Funding Approaches, 2007 92
Table 3-1: The U.S. Market for Retail Clinic Services, 2001-2011
CHAPTER THREE: SERVICE PROVIDERS
Figure 3-1: Growth of U.S. Retail Clinic Services, 2001-2011
Table 3-2, Leading Service Providers’ Revenues and Market Share
Figure 3-2: Market Shares of Leading Retail Clinic Service Provider, 2006
CHAPTER FOUR: OPPORTUNITIES FOR DIAGNOSTIC AND PHARMACEUTICAL COMPNIES
Table 4-1: Sales to Retail Clinics by Supplier Segment, 2001-2011 (POC Tests, Clinical Chemistry & Immuno-
assays, Vaccines)
Figure 4-1: Growth of Retail Clinic Supplier Sales by Type of Supplies, 2001-2011 (POC Tests, Clinical
Chemistry & Immuno-assays, Vaccines)
Table 4-2: U.S. Professional POC Test Sales, 2001-2011
Table 4-3: Leading POC Test Makers’ U.S. Revenues and Markert Share, 2006
Table 4-4: U.S. Professional POC Test Sales to Retail Clinics, 2001-2011
Table 4-5: U.S. Clinical Chemistry and Immunoassay Sales, 2001-2011
Table 4-6: Leading Clinical Chemistry and Immunoassay Suppliers’ Revenues and Market Share, 2006
Table 4-8: Diseases for which Vaccines are Available in the U.S., 2007
Table 4-9: U.S. Market for Preventative Vaccines, 2001-2011
Table 4-10: Leading Vaccine Manufacturers’ U.S. Revenues and Market Share, 2007
Table 4-11: U.S. Vaccine Sales to Convenience Clinics, 2001-2011
CHAPTER FIVE: RETAIL OUTLETS
Table 5-1: Number of Retail Clinics by Type of Retail Outlet (Drug Stores, Supermarkets, Mass Merchandising
Outlets, Other), 2001-2011
Figure 5-2: Proportion of Rents Collected From Retail Clinics by Type of Retail Outlet, 2001-2011 (Drug Stores,
Supermarkets, Mass Merchandising Outlets, Others)
Table 5-3: Indirect Income Generated by Retail Clinics by Type of Retail Outlet, 2001-2011, (Drug Stores,
Supermarkets, Mass Merchandising Outlets, Others)
Figure 5-3: Proportion of Indirect Income Generated by Retail Clinics by Type of Retail Outlet, 2001-2011
(Drug Stores, Supermarkets, Mass Merchandising Outlets, Others)
Table 5-4: Selected Retail Outlet Relationships with Convenience Clinics, 2007
Table 5-5: U.S. Drug Store Sales, 2001-2011
Table 5-6 Leading U.S. Drug Stores’ Revenues and Market Share, 2006
Table 5-7: U.S. Drug Store Direct Retail Clinic Revenues, 2001-2011 (No. of Stores, Sq. Ft Per Store, Cost Per
Sq. Ft.)
Table 5-8: U.S. Drug Store Indirect Retail Clinic Revenues, 2001-2011 (Number of Clinics, Patients/Clinic/Day,
Incremental Sales per Patient, Total Indirect Revenue)
Figure 5-4: Direct vs. Indirect Revenues to Drug Stores From Retail Clinics, 2001-2011
Table 5-9: U.S. Food Store Sales, 2001-2011
Table 5-10: Leading Food Stores Revenues and Market Share, 2006
Table 5-11: U.S. Food Stores Direct Retail Clinic Revenues, 2001-2011 (No. of Stores, Sq. Ft Per Store, Cost Per
Sq. Ft.)
Table 5-12: U.S. Food Store Indirect Retail Clinic Revenues, 2001-2011 (Number of Clinics, Patients/Clinic/Day,
Incremental Sales per Patient, Total Indirect Revenue)
Figure 5-5: Direct vs. Indirect Revenues to Food Stores from Retail Clinics, 2001-2011
Table 5-13: U.S. Mass Merchandiser Sales, 2001-2011
Table 5-14: Leading Mass Merchandisers Revenues and Market Share, 2006
Table 5-15: U.S. Mass Merchandiser Retail Clinic Revenues (No. of Stores, Sq. Ft Per Store, Cost Per Sq. Ft.)
Table 5-16: U.S. Mass Merchandiser Indirect Retail Clinic Revenues, 2001-2011 (Number of Clinics,
Patients/Clinic/Day, Incremental Sales per Patient, Total Indirect Revenue)
Table 5-17: U.S. Other Retail Sales, 2001-2011
Table 5-18: Leading Other Outlets Revenues and Market Share, 2006
Table 5-19: US Other Outlets Direct Retail Clinics Revenues (No. of Stores, Sq. Ft Per Store, Cost Per Sq. Ft.)
Table 5-20: U.S. Other Outlets Indirect Retail Clinic Revenues (Number of Clinics, Patients/Clinic/Day,
Incremental Sales per Patient, Total Indirect Revenue)
CHAPTER SIX: MARKET SUMMARY
Table 6-1: Retail Clinic Service Revenues, 2001-2011
Table 6-2: Sales to Retail Clinics by Suppliers 2001-2011
Figure 6-1: Revenues from Retail Clinics (Direct Rents/Indirect Revenues)
CHAPTER SEVEN: ISSUES AND TRENDS
Table 7-1: Selected U.S. Federal and State Health Care Oversight Bodies, 2007
DNA SEQUENCING EQUIPMENT AND SERVICES MARKETS
CHAPTER ONE: EXECUTIVE SUMMARY
DNA Sequencing Applications
Types of Samples
Market Trends
Scope and Methodology
CHAPTER TWO: INTRODUCTION
Background
DNA Sequencing Applications
Types of Samples
DNA Sequencing Strategies
DNA Sequencing Chemistries and Techniques
Sanger Sequencing
Single Nucleotide Addition; Pyrosequencing
Cyclic Reversible Terminators
CHAPTER THREE: SEQUENCER MARKET TRENDS AND FUNDING TRENDS
Market Trends
Market Fragmenting Into Multiple Applications, Products
Synergies Appearing Between Companies’ Products
Microbes and Metagenomics Gaining Importance
Various Disruptive Technologies Rapidly Appearing On Market
Miniaturization of Sanger and CE Technology
Paired-End Techniques, Increasing Read-Lengths Expanding Applications
Development of Multiplexing Approaches Extends Market
SNP and Other Experiments Moving to Sequencing for Higher Detail
Continued Rapid Growth in Sequence Production
Funding Trends
Funding and Consortia for Sequencing
The Cancer Genome Atlas Pilot Project
Cancer Sequencing Project
FUGE - Functional Genomics in Norway
NSF / USDA Microbial Genome Sequencing Program
OTHER FUNDING
CHAPTER FOUR: DNA SEQUENCER PRODUCTS
454 Life Sciences (Branford, CT) / Roche
Genome Sequencer 20
Genome Sequencer FLX
Applied Biosystems (Foster City, CA)
ABI Prism 310 Genetic Analyzer
ABI Prism 3100-Avant Genetic Analyzer
Applied Biosystems 3100 Genetic Analyzer
Applied Biosystems 3130 Genetic Analyzer
Applied Biosystems 3130xl Genetic Analyzer
Applied Biosystems 3730 DNA Analyzer
Applied Biosystems 3730xl DNA Analyzer
SOLiD (early access)
Beckman Coulter
CEQ 8000; CEQ 8800
GE Healthcare
MegaBACE 500
MegaBACE 750
MegaBACE 1000
MegaBACE 1500
MegaBACE 4000
Illumina / Solexa
Illumina Genome Analyzer
LI-COR Biosciences (Lincoln, NE)
4300
CHAPTER FIVE: MARKET DATA
Revenues and Forecast
CHAPTER SIX: COMPETITIVE ANALYSIS
Features and Strengths of Next-Generation Sequencers
454 Life Sciences - Strengths / Advantages
454 Life Sciences - Weaknesses / Disadvantages
Applied Biosystems SOLiD - Strength / Advantages
Applied Biosystems SOLiD - Weaknesses / Disadvantages
Illumina Genome Analyzer - Strength / Advantages
Illumina Genome Analyzer - Weaknesses / Disadvantages
CHAPTER SEVEN: INTELLECTUAL PROPERTY AND LITIGATION
Affymetrix Wins Patent Infringement Case Against Illumina
Applied Biosystems and Amersham plc (GE Healthcare) Settle Sequencing Patent Litigation
Applied Biosystems Sues Solexa and Former Chief Patent Counsel
Beckman Coulter and Applied Biosystems Settle Outstanding Legal Disputes
Cepheid and Idaho Technology Settle Dispute Over PCR Patents
Enzo Biochem Disputes CalTech Sequencing Patents
Huang v. CalTech
CHAPTER EIGHT: DEALS
CHAPTER NINE: CORPORATE PROFILES
454 Life Sciences (Branford, CT) / Roche
Applied Biosystems (Foster City, CA)
Beckman Coulter (Fullerton, CA)
GE Healthcare Life Sciences (Little Chalfont, UK)
Helicos Biosciences (Cambridge, MA)
Illumina / Solexa
Intelligent Bio-Systems (Waltham, MA)
LI-COR Biosciences (Lincoln, NE)
NABsys (Providence, RI)
CHAPTER TEN: TECHNOLOGIES UNDER DEVELOPMENT
NHGRI Funds Next Generation of Sequencing Technologies
454 Life Sciences Corp
“Massively Parallel High Throughput, Low Cost Sequencing”
“454 Life Sciences Massively Parallel System DNA Sequencing”
Agencourt Personal Genomics [Applied Biosystems]
“Bead-based Polony Sequencing”
Arizona State University, Tempe
“Multiplexed Reactive Sequencing of DNA”
Baylor College of Medicine, Human Genome Sequencing Ctr
“Ultrafast SBS Method for Large-Scale Human Resequencing”
Columbia University
“An Integrated System for DNA Sequencing by Synthesis”
Harvard University, Rowland Institute; moved to Boston Univ
“Ultra-fast Nanopore Readout Platform for Designed DNA's”
LI-COR Inc
“Single-Molecule DNA Sequencing Using Charge-Switch dNTPs”
Microchip Biotechnologies Inc
“Microbead INtegrated DNA Sequencer (MINDS) System”
Stanford University
“High-Throughput, Single-Molecule DNA Sequencing”
Stanford Genome Technology Center
“Pyrosequencing Array for DNA Sequencing”
University of Gainesville, Florida
“DNA Sequencing Using Nanopores”
“Polymerases for Sequencing by Synthesis”
Second Group of Grants, $1000 Genome
Arizona State University, Tempe
“Molecular Reading Head for Single-Molecule DNA Sequencing”
Oak Ridge National Laboratory
“Experimental R&D for Rapid Sequencing Nanotechnology”
“Computational R&D for Rapid Sequencing Nanotechnology”
Stanford University
“Single Molecule Nucleic Acid Detection with Nanopipettes”
University of British Columbia, Vancouver
“Nanopores for Trans-Membrane Bio-Molecule Detection”
University of Maine, Orono
“High-speed Nanopore Gene Sequencing”
University of North Carolina, Chapel Hill
“Nanotechnology for the Structural Interrogation of DNA”
NHGRI Expands Effort to Revolutionize Sequencing Technologies
Agencourt Personal Genomics [Applied Biosystems]
“Bead-Based Polony Sequencing (Supplemental)”
Network Biosystems
“$100,000 Genome Using Integrated Microfluidic CE”
The State University of New York, Stony Brook (SUNY)
“Ultra High Throughput DNA Sequencing System Based on 2D Monolith Multi-Capillary Arrays and Nanoliter
Reaction Volume”
Columbia University
“Modulating Nucleotide Size in DNA for Detection by Nanopore”
Duke University
“Droplet-Based Digital Microfluidic Genome Sequencing”
Harvard University
“Electronic Sequencing in Nanopores”
Nanofluidics
“Real-Time Multiplex Single-Molecule DNA Sequencing”
New York University
“Haplotype Sequencing Via Single Molecule Hybridization”
Oxford University and The Scripps Research Institute
“Single-Molecule DNA Sequencing with Engineered Nanopores”
University of California, San Diego
“Massively Parallel Cloning and Sequencing of DNA”
University of Illinois at Urbana-Champaign
“Sequencing a DNA Molecule Using a Synthetic Nanopore”
VisiGen Biotechnologies
“Real-Time DNA Sequencing”
“NHGRI Aims to Make DNA Sequencing Faster, More Cost Effective”, October 2006
“Fabrication of Universal DNA Nanoarrays for Sequencing by Hybridization”
Boston University
“High-Throughput DNA Sequencing Using Design Polymers and Nanopore Arrays”
Case Western Reserve University
“Large-Scale Nanopore Arrays for DNA Sequencing”
General Electric Global Research
“Closed Complex Single Molecule Sequencing”
Helicos Biosciences
“High Accuracy Single Molecule DNA Sequencing by Synthesis”
Lehigh University
“Force Spectroscopy Platform for Label Free Genome Sequencing”
University of California, San Diego
“Genome Sequencing by Ligation Using Nano-Arrays of Single DNA Molecules”
University of North Carolina, Chapel Hill
“Nanoscale Fluidic Technologies for Rapidly Sequencing Single DNA Molecules”
University of Washington, Seattle
“Engineering MspA for Nanopore Sequencing”
Baylor College of Medicine, HGSC
“Ultrafast SBS Method for Large-Scale Human Resequencing”
Intelligent Bio-Systems
“High-Throughput DNA Sequencing by Synthesis Platform”
Other Microfluidics and Lab-on-a-Chips
CHAPTER ELEVEN: CHALLENGES AND STRATEGIC RECOMMENDATIONS
Market Challenges
Saturation, Technology Advances Threaten Market Growth
Next-Generation Vendors Contending With 454’s Head-Start
Rapid Changes, Multiple Variables Creating Unpredictable Market
Labs Hesitant to Invest in Unproven Technologies
Segments Resisting Change Where Long Read-Lengths Key
New Technologies Create Data Management Issues
Recent Acquisitions Make Tougher Environment for New Entrants
Strategic Recommendations
Increase Products’ Value Through Software Tools
Explore Demand in Expanding Industry Segments
Address Niche Markets Resulting From Fragmentation
Increase Value by Combining with Complementary Content
Establish Early Connections With End-Users
Balance Risks by Diversifying Applications
Move Towards Diagnostic Environment Requires Partnering
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1: DNA Sequencer Equipment Revenues 1999-2006
Figure 1-1: Trending in the DNA Sequencer Equipment Market 2006-2012
CHAPTER THREE: SEQUENCER MARKET TRENDS AND FUNDING TRENDS
Figure 3-1: Distribution of Archaeal and Bacterial Genome Projects, Q1 2007 (JGI, TIGR, J Venter, World)
Figure 3-2: Phylogenetic Distribution of Bacterial Genome Projects, Q1 '07
Figure 3-3: Number of Completely Sequenced Genomes (Published vs Unpublished) 1999 through Q1 2007
Figure 3-4: Distribution of Number of Projects Among Major Sequencing Centers Q1 2007
Figure 3-5: Funding by the Top Agencies in DNA Sequencing
Figure 3-6: U.S. Funding for the Human Genome Project DOE vs NIH 1990-2003
Figure 3-7: Distribution of the Number of Bacterial Sequencing Projects by Area of Focus (Agriculture/Food,
Biomedical, Biotech, Environmental, Evolutionary)
Table 3-1: FUGE Funding Recipients
Table 3-2 Large-Scale Sequencing Centers NHGRI Funding, 2007
Figure 3-8: NHGRI Funding of Large-Scale Sequencing Centers by Organization 2004-2006 (cumulative)
Figure 3-9: NHGRI Funding of Large-Scale Sequencing Centers by Organization 2007
Figure 3-10: Broad Institute Organizational Structure
Table 3-3: NSF Plant Genome Research Project Recent Funding Awards (Title Start Date, Expiration Date, PI,
Organizatino, Funding Amount)
Table 3-4: NSF / USDA Microbial Genome Sequencing Program Recent Funding Awards (Title, Start Date,
Expiration Date, PI, Organization, Funding Amount)
CHAPTER FOUR: DNA SEQUENCER PRODUCTS
Table 4-1: Key Products and Technologies Currently on the Market by Company (Company, Product/
Technology, Comments)
CHAPTER FIVE: MARKET DATA
Table 5-1: DNA Sequencer Equipment Revenues 1999-2006
Table 5-2: DNA Sequencer Equipment Revenues 2006-2012
Figure 5-1 DNA Sequencer Market, Market Share by Industry, 2006
Figure 5-2: Trending in the DNA Sequencer Equipment Market 1999-2006
Figure 5-3: ABI’s Quarterly Overall Sequencing Revenues 2001 to 2006
Figure 5-4: ABI’s Quarterly Overall Sequencing Revenues Q3 2005 to Q4 2006
Figure 5-5: Estimated Forecasted Price of Sequencing a Genome 1990-2030
Figure 5-6: Trending in the DNA Sequencer Equipment Market, 2006-2012
CHAPTER SIX: COMPETITIVE ANALYSIS
Table 6-1: Revenues and Market Shares of Leading DNA Sequencer System Suppliers, 2006 (Company,
Market Share, Revenues, Trend)
Figure 6-1: Market Shares, DNA Sequencer Systems, 2006
Table 6-2: Comparison of Next-Generation Sequencer System Features (Reads, Read Length, Number of
Samples at Once, BP Output, Cost Comparison with Sanger/ CE, Consumable Cost per Run)
CHAPTER SEVEN: INTELLECTUAL PROPERTY AND LITIGATION
Table 7-1: Selected Sequencing-Related Patents Assigned or Licensed to Applied Biosystems (Assignee, Title,
Patent #)
CHAPTER EIGHT: DEALS
Table 8-1: Notable Deals in Recent Years (Companies, Date, Details)
CHAPTER TEN: TECHNOLOGIES UNDER DEVELOPMENT
Table 10-1: First Set of NHGRI “$100,000 Genome” Grant Awardees October 2004 (Awardee, Title, Amount,
Term)
Table 10-2: First Set of NHGRI “$1,000 Genome” Grant Awardees October 2004 (Awardee, Title, Amount,
Term)
Table 10-3: Second Set of NHGRI “$100,000 Genome” Grant Awardees August 2005 (Awardee, Title, Amount,
Term)
Table 10-4: Second Set of NHGRI “$1,000 Genome” Grant Awardees August 2005 (Awardee, Title, Amount,
Term)
Table 10-5: Latest Set of NHGRI “$1,000 Genome” Grant Awardees October 2006 (Awardee, Title, Amount,
Term)
Table 10-6: Latest Set of NHGRI “$100,000 Genome” Grant Awardees October 2006 (Awardee, Title, Amount,
Term)
Table 10-7: Selected Group s Workingon Microfluidics for DNA Sequencing Applications (Number of
Channels, Read Length, Time)
Ordering:
Order Online - http://www.researchandmarkets.com/reports/2860766/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from
USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/
Order Information
Please verify that the product information is correct and select the format(s) you require.
Product Name:
Testing Services Markets, SNP Analysis, DNA Sequencing, Retail Clinics, Companion
Diagnostics
Web Address:
http://www.researchandmarkets.com/reports/2860766/
Office Code:
SCHL3FA7
Product Formats
Please select the product formats and quantity you require:
Quantity
Electronic (PDF) Single User:
USD 2995
Electronic (PDF) Enterprisewide:
USD 5000
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title:
First Name:
Mr
Mrs
Dr
Miss
Last Name:
Email Address: *
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Ms
Prof
Page 2 of 2
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by credit card:
You will receive an email with a link to a secure webpage to enter your
credit card details.
Pay by check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.
Pay by wire transfer:
Please transfer funds to:
Account number
833 130 83
Sort code
98-53-30
Swift code
ULSBIE2D
IBAN number
IE78ULSB98533083313083
Bank Address
Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at
http://www.researchandmarkets.com/info/terms.asp
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World